<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mephentermine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01365</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01365/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01365/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01365.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01365.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01365.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01365.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01365.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01365">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Mephentermine sulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001074/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001074/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001074">DBSALT001074</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Wyamine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Wyfentermina</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/vasoconstrictor-agents">Vasoconstrictor Agents</a></li>
<li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li>
<li><a href="/mesh/adrenergic-alpha-1-receptor-agonists">Adrenergic alpha-1 Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>100-92-5</td></tr><tr><th>Weight</th><td>Average: 163.2594<br>Monoisotopic: 163.136099549</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>17</sub>N</td></tr><tr><th>InChI Key</th><td>RXQCGGRTAILOIN-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">methyl(2-methyl-1-phenylpropan-2-yl)amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CNC(C)(C)CC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01365.gif?1265922772">show</a>(7.87 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>polyamine; secondary aliphatic amine; secondary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used to maintain blood pressure in hypotensive states.</td></tr><tr><th>Pharmacodynamics</th><td>Mephentermine is a sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)</td></tr><tr><th>Mechanism of action</th><td>Mephentermine is an alpha adrenergic receptor agonist, but also acts indirectly by releasing endogenous norepinephrine. Cardiac output and systolic and diastolic pressures are usually increased. A change in heart rate is variable, depending on the degree of vagal tone. Sometimes the net vascular effect may be vasodilation. Large doses may depress the myocardium or produce central nervous system (CNS) effects.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, by N-demethylation and then p-hydroxylation.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>17 to 18 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9925</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9664</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7962</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5711</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9574</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.775</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7797</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.7109</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5507</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.979
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8079
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9633
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.8952 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9804
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.872
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Possible increase of arterial pressure</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Moclobemide increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of mephentermine.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00206">Reserpine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Trimipramine may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>